1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 3:MR imaging features of metastatic brain lesions
Melanoma Lung Total lesion number 120 120 Susceptibility effect 42% (50/120) 8% (10/120) (P < .01) Amelanotic/slightly 49% (17/35)* Heavily melanotic 33% (10/30)† (P = .4) Hyperintense T1WI 55% (66/120) 12% (15/120) (P < .01) Amelanotic/slightly 49% (17/35) Heavily melanotic 83% (25/30) (P < .01) Enhancement 78% (94/120) 98% (118/120) (P = .02) Edema 68% (82/120) 66% (80/120) (P = .56)
* Total of 35 lesions in 20 patients with biopsy material.
† Total of 30 lesions in 20 patients with biopsy material.